N. Klimas et al., CLINICAL AND IMMUNOLOGICAL CHANGES IN AIDS PATIENTS FOLLOWING ADOPTIVE THERAPY WITH ACTIVATED AUTOLOGOUS CD8 T-CELLS AND INTERLEUKIN-2 INFUSION, AIDS, 8(8), 1994, pp. 1073-1081
Objectives: (1) To determine the safety and feasibility of repetitive
reinfusions of activated autologous CD8 cells followed by low-dose con
tinuous interleukin (IL)-2 infusion in patients with AIDS. (2) To stud
y the relationships between clinical responses, surface marker phenoty
pic distributions and cytokine expression patterns of both cultured CD
8 cells and lymphocytes in the peripheral blood compartment. Design: S
ix adult patients with Centers for Disease Control and Prevention grou
p IV HIV-1 disease ranging from mild to severe, were studied. All pati
ents were receiving zidovudine prior to and during the study period, a
nd had initial CD4 and CD8 cell counts > 50 and 200 x 10(6)/l, respect
ively. Methods: Autologous CD8 T cells (10(8)-10(10)) were reinfused f
ive times after ex vivo culture and stimulation with phytohemagglutini
n and recombinant (r) IL-2. The fifth such infusion was followed by 5
days of rlL-2 infusion. Phenotypes and cytokine expression patterns of
the expanded cells were determined as well as serum levels of immune
mediators throughout the study. Results: Patients showed stable CD4 an
d CD8 cell counts, p24 antigenemia, and minimal toxicity over the 24-w
eek protocol study. Clinical improvement was observed in lymphadenopat
hy (six out of six), oral hairy leukoplakia (three out of four), and K
aposi's sarcoma (KS; two out of two) in the patients studied. In vivo
induction of detectable levels of bioactive acid-stable interferon (IF
N)-alpha, but not of other cytokines studied, upon activated CD8 cell
reinfusion was associated consistently with improvement of oral hairy
leukoplakia. However, partial regression of KS was observed after the
CD8 cell infusion cycles and without IFN-alpha induction. In one of th
e two patients studied, KS regression was associated with decreased IL
-1 alpha serum levels. In the other patient, who had failed previous I
FN-alpha therapy, KS regression was observed after a decline in reinfu
sed CD8 cell-associated gene expression of tumor necrosis factor (TNF)
-beta. Both IL-1 alpha and TNF-beta are growth factors for KS cells. C
onclusions: These observations demonstrate the feasibility and safety
of ex vivo CD8 cell activation, expansion, and reinfusion, and rlL-2 i
nfusion in AIDS patients. The findings in this Phase I trial suggest p
otential clinical efficacy and encourage Phase II trials. The correlat
ions obtained between clinical and immunological states could contribu
te to an understanding of the relationship between CD8 T-cell function
and HIV-1-associated disease progression.